Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
September 2018
-
Media ReleaseNovartis survey shows psoriasis patients want treatment effect beyond clear skinNew patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Media ReleaseAlcon confirms commitment to Switzerland ahead of proposed spinoff from NovartisGlobal headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…
-
Media ReleaseAlcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der SchweizDer globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…
-
Media ReleaseAlcon confirme son engagement envers la Suisse en perspective de la scission proposée avec NovartisLe siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon…
-
Nudging bias out of the organization
Our Global Head of Talent Acquisition & Staffing talks about ongoing recruitment efforts to create a more diverse and inclusive organization.
-
Key ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to AurobindoNovartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
August 2018
-
The ABCDEs of melanoma prevention and detection
Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.
-
Media ReleaseEuropean Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanomaApproval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma…
-
Key ReleaseAlcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucomaDecision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
-
Teaming up with academia to discover medicines
The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.
-
Media ReleaseNovartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
-
Media ReleaseNovartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen KommissionDie Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- …
- 151
- › Next page